Fw: Review of Alizect trials (Adagio)

["ljherman1@xxxxxxxx" <ljherman1@xxxxxxxx>]

Recently published review of Azilect clinical trial (Adagio) in the lanc=
et.neurology (Vol 8 December 2009, )found that while it used an interest=
ing trial design, this study  didn't end the uncertainty  over whether A=
zilect offers  neuroprotection and to whom. =


"ADAGIO misses a beat?" by Karl Kieburtz, Lancet Neurology, dec. 2009.
excerpt:
" Uncertainty is not a satisfying result. The results of this study1 and=
 TEMPO2 will certainly lead some clinicians to
use rasagiline for its known symptomatic benefi t and the possibility of=
 slowing PD disease progression. Other
clinicians will use established PD therapies (eg, levodopa) that also ha=
ve some hint of slowing PD progression
and are less costly. The uncertainty should be settled by further invest=
igation of both the 1 mg dose and the
2 mg dose, learning from the lessons of previous studies. Although the i=
nvestigators should be congratulated for a
considerable research accomplishment, the implications for patient care =
remain uncertain."
I was prescribed .5 mil/day, as an adjunct to levodopa. but I haven't no=
ticed any symptom improvment . I'm am hoping it truly is neuroprotective=
,even at this lower dose. (higher than .5 mil  increased dyskinesia. ) S=
eems the jury is still out....
linda =

 =


----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn